Intravitreal injection of bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, either as primary or adjuvant therapy for diabetic macular edema and proliferative diabetic retinopathy.
Vascular endothelial growth factor (VEGF) is a major driving force in the development of diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR). Intravitreal injection of the anti-VEFG medication bevacizumab (Avastin) has revolutionized the treatment of diabetic eye disease, and has emerged as an important treatment modality, either as primary or adjuvant therapy for DME and PDR.
The reference Avastin was approved to treat cancer, as was its biosimilar (Mvasi), but its off-label use to treat diabetic retinopathy remains popular and widespread around the world, especially in low-income countries, given its lower cost, perceived effectiveness, and comparable safety profile.
Writing for the Pan-American Collaborative Retina Study Group (PACORES), J. Fernando Arevalo, MD, and T.Y. Alvin Liu, MD, reviewed 5 years of experience using intravitreal bevacizumab for diabetic retinopathy in Latin America and Spain, and conclude that it is an important tool in the armamentarium for treating the complications of diabetic retinopathy.
The researchers add that intravitreal bevacizumab can also be used as a preoperative, adjuvant therapy before vitrectromy for proliferative diabetic retinopathy. Their study provides one of the longest-term follow-up data sets on the efficacy of the anti-VEGF treatments in DME. The review is published in the December 2017 issue of Asia-Pacific Journal of Ophthalmology (Philadelphia).
Their study enrolled 201 patients (296 eyes) with center-involving DME and vision loss who were treated monthly with 1.25 mg of intravitreal bevacizumab until edema was stabilized, then returned to clinic and treated on an as-needed regimen, based on best corrected visual acuity (BCVA) and optical coherence tomography (OCT). The main outcome measures were changes in BCVA and central macular thickness (CMT) at the 60-month follow-up visit.
The group’s data on preoperative intravitreal bevacizumab suggest that it is beneficial before vitrectomy for PDR, as it tends to decrease intraoperative bleeding, facilitate intraoperative fibroproliferative membrane dissection, and decrease postoperative bleeding. The researchers believe intravitreal bevacizumab before vitrectomy is safe, especially with careful planning and patient selection.
“Based on our experience, we recognize intravitreal bevacizumab to be an important tool in our armamentarium for treating the complications of diabetic retinopathy,” they conclude. “For center-involving DME, our real-world data suggest that there is a roughly 70% chance of stabilized or improved vision with intravitreal bevacizumab treatments over a time course of 5 years,” they write, adding that for PDR, intravitreal bevacizumab is a good adjuvant therapy for patients who have already received prior panretinal photocoagulation treatment. Finally, they conclude that preoperative intravitreal bevacizumab before vitrectromy is safe, with a low incidence of development or progression of tractional retinal detachment.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.